Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Blood

Volumn 122, Issue 6, 2013, Pages 981-987

  Tan, Daryl ^a   Horning, Sandra J ^a   Hoppe, Richard T ^b   Levy, Ronald ^a   Rosenberg, Saul A ^a   Sigal, Bronislava M ^a   Warnke, Roger A ^a   Natkunam, Yasodha ^a   Han, Summer S ^a   Yuen, Alan ^a   Plevritis, Sylvia K ^a   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LYMPHOMA VACCINE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; AGED; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL; UNITED STATES; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CALIFORNIA; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886644562     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491514     Document Type: Article

References (37)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89(11): 3909-3918.
2. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984; 311(23): 1471-1475. (Pubitemid 15211022)
3. Acker B, Hoppe RT, Colby T.V., Cox RS, Kaplan HS, Rosenberg SA. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol. 1983; 1(1): 11-16. (Pubitemid 13066136)
4. Garvin AJ, Simon RM, Osborne C.K., Merrill J., Young RC, Berard CW. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983; 52(3): 393-398. (Pubitemid 13073462)
5. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011; 29(14): 1827-1834.
6. Tan D, Rosenberg SA, Lavori P. Improved prognosis after histologic transformation of follicular lymphoma: the Stanford experience 1960-2003. Ann Oncol 2008; 19(111) (Suppl 4): abstract 89.
7. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20(5 Suppl 5): 75-88. (Pubitemid 23319044)
8. Fisher RI, LeBlanc M, Press O.W., Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005; 23(33): 8447-8452.
9. Swenson WT, Wooldridge JE, Lynch C.F., Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005; 23(22): 5019-5026. (Pubitemid 46224008)
10. Liu Q, Fayad L, Cabanillas F., et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006; 24(10): 1582-1589. (Pubitemid 46638782)
11. Marcus R, Imrie K, Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105(4): 1417-1423. (Pubitemid 40223656)
12. Hiddemann W, Kneba M, Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106(12): 3725-3732. (Pubitemid 41742196)
13. Salles G, Mounier N, de Guibert S, et al. Final Analysis of the GELA-GOELAMS FL2000 Study with a 5-Year Follow-Up. Blood. 2007; 110(792a).
14. Herold M, Haas A, Srock S., et al.; East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007; 25(15): 1986-1992. (Pubitemid 46972781)
15. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26(28): 4579-4586.
16. Hochster H, Weller E, Gascoyne R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009; 27(10): 1607-1614.
17. Jaffe ES H.N., Stein H, Vardiman JW ed World Health Organisation classification of tumours: Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001.
18. Brice P, Bastion Y, Lepage E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3): 1110-1117. (Pubitemid 27106296)
19. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104(5): 1258-1265. (Pubitemid 39166497)
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1958; 53: 457-484.
21. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. 1973; 29(3): 579-584.
22. Human Mortality Database University of California, Berkeley (USA) and Max Planck Institute for Demographic Research (Germany). Available at: http://www.mortality.org or http://www.humanmortality.de Accessed October 16, 2011.
23. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101-121.
24. Voutilainen ET, Dickman PW, Hakulinen T. SURV2: Relative Survival Analysis Program, version 3. Vol Version 3. Helsinki, Finland: Finnish Cancer Registry; 1998.
25. Friedberg JW, Taylor MD, Cerhan J.R., et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27(8): 1202-1208.
26. Solal-Céligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996; 14(2): 514-519. (Pubitemid 26051015)
27. McLaughlin P, Hagemeister FB, Romaguera J.E., et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996; 14(4): 1262-1268. (Pubitemid 26105534)
28. Velasquez WS, Lew D, Grogan T.M., et al.; Southwest Oncology Group. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 2003; 21(10): 1996-2003. (Pubitemid 46606389)
29. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 1997; 89(9): 3129-3135.
30. Conconi A, Motta M, Bertoni F., et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma. 2010; 51(6): 1028-1034.
31. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008; 112(13): 4824-4831.
32. Bachy E, Brice P, Delarue R., et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol. 2010; 28(5): 822-829.
33. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007; 99(9): 706-714. (Pubitemid 47078732)
34. Sacchi S, Pozzi S, Marcheselli L., et al.; Italian Lymphoma Study Group. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007; 109(10): 2077-2082. (Pubitemid 46744202)
35. Federico M, Vitolo U, Zinzani P.L., et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000; 95(3): 783-789. (Pubitemid 30062696)
36. Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson PO. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study. Leuk Lymphoma. 2007; 48(4): 736-745. (Pubitemid 46605546)
37. Müller C., Murawski N, Wiesen M.H., et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012; 119(14): 3276-3284.